Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Hypertension. 2019 Dec 23;75(2):492–499. doi: 10.1161/HYPERTENSIONAHA.119.14062

Figure 6.

Figure 6.

CLGN silencing by CRISPR/Cas9 technology had no effect on aldosterone production in HAC15 cells. (A) CLGN mRNA expression was analyzed in HAC15 cells with control (sg-Control) or knock-down CLGN (KD-CLGN). (B) CLGN protein levels were evaluated by western blot in control and KD-CLGN cells. CLGN protein levels were adjusted by β-actin, and the protein levels in KD-CLGN cells were expressed as fold change vs. control cells (C) Relative aldosterone levels between control and KD-CLGN cells +/− angiotensin II (A-II) stimulation or KCNJ5 mutation (KCNJ5 mut) transduction. Results are shown as fold change vs. control cells. *P < 0.05 vs. control (n = 3).